Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 5;32(1):68-72.
doi: 10.4274/tjh.2012.0196.

Dasatinib-related chylothorax

Yen Min Huang  1 , Cheng Hsu Wang, Jen Seng Huang, Kun Yun Yeh, Chien Hong Lai, Tsung Han Wu, Pei Hung Chang, Pei Hung Chang, Yueh Shih Chang, Yii Jenq Lan
Affiliations

Dasatinib-related chylothorax

Yen Min Huang et al. Turk J Haematol. .

Abstract
in English, Turkish

Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The most common adverse event associated with dasatinib therapy is fluid retention, including pleural effusion. Dasatinib-related chylothorax has rarely been reported. The clinical manifestations, pathophysiology, management, and prognosis are not fully understood. Here we report a 40-year-old woman presenting with chylothorax following dasatinib use. We propose the hypothesis of its mechanism as well as offering a review of the relevant literature.

Dasatinib kronik miyeloid lösemi tedavisinde kullanılan etkin bir ikinci kuşak tirozin kinaz inhibitörüdür. Dasatinib tedavisi ile ilişkili en sık görülen yan etki plevral effüzyonu da içeren sıvı retansiyonudur. Dasatinib ile ilişkili şilotoraks nadiren bildirilmiştir. Klinik belirtileri, patofizyolojisi, yönetimi ve prognozu tam olarak anlaşılamamıştır. Burada dasatinib kullanımı sonrasında şilotoraks gelişimi ile başvuran 40 yaşında bir kadın sunulmuştur. Dasatinib ile ilişkili şilotoraks gelişiminin mekanizmasının yanı sıra, konu ile ilgili literatür derlemesinden de bahsedilmektedir.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

Figures

Figure 1
Figure 1. Chest radiography: A) initial small pleural effusion; B) 9 days later after diuretics and steroid treatment; C) recurrent pleural effusion after dasatinib was resumed; D) 6 weeks after dasatinib interruption.
See this image and copyright information in PMC

References

    1. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipiña JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Blood. 2012;119:1123–1129. - PMC - PubMed
    1. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116:377–386. - PMC - PubMed
    1. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol. 2010;85:164–170. - PubMed
    1. Light RW, Macgregor MI, Luchsinger PC, Ball WC., Jr Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77:507–513. - PubMed
    1. Keam SJ. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. BioDrugs. 2008;22:59–69. - PubMed

LinkOut - more resources